In this Issue:
Empagliflozin, CV outcomes and mortality in type 2 diabetes
Empagliflozin as adjunct to insulin in type 1 diabetes
Diabetes prevalence and trends in US adults
Early glycaemic control with add-on metformin
Missing breakfast increases glycaemia later in the day
Adding empagliflozin to basal insulin in type 2 diabetes
Insulin pen underdelivery with premature needle withdrawal
Excess mortality in type 2 diabetes
Severe hypoglycaemia requiring emergency treatment in Spain
Rosiglitazone and CV disease in US veterans
Please login below to download this issue (PDF)